NCT03342937

KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will be conducted in two stages: 1) safety validation and 2) dose expansion 1. Safety Validation Cohort: The first portion of the study will preliminarily establish the tolerability of the combination of pembrolizumab, oxaliplatin and capecitabine. Five (5) subjects will be enrolled and their safety data after 21 days of treatment will be reviewed before additional subjects are enrolled. Subjects on this portion of the study will only be enrolled at the Duke Cancer Institute. 2. Dose Expansion Cohort: The second portion of the study (ie. phase II) will enroll 30 subjects. In the dose expansion cohort, the first cycle will be modified to allow one week of pembrolizumab monotherapy before starting capecitabine and oxaliplatin (XELOX) chemotherapy, which will allow analysis of biomarkers related to pembrolizumab. Subjects on this portion of the study will be enrolled at the Duke Cancer institute and select external collaborating institutions. The primary objective of this trial is to describe the progression free survival (PFS) associated with the combination of pembrolizumab, oxaliplatin and capecitabine (pembrolizumab +XELOX) in all patients with previously untreated metastatic esophagogastric adenocarcinoma.

Conditions

• Gastric Cancer
• Esophagus Cancer

Interventions

Type	Name	Description
DRUG	Oxaliplatin+Capecitabine+Pembrolizumab	For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1. This study has 2 parts: 1. Safety validation part: all Cycles are 21 days in length. 2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days.

Timeline

• Start date: 2018-01-11
• Primary completion: 2023-02-06
• Completion: 2023-02-06
• First posted: 2017-11-17
• Last updated: 2024-03-13
• Results posted: 2024-03-13

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study